ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Celltrion, Inc.

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

 

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

 

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

 

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2021 KRWUSD
Revenue1,911.60B1,669.28M
Gross Profit1,064.37B929.45M
Operating income752,471.48M657.08M
Income before tax751,917.45M656.60M
Net income575,093.26M502.19M
EBITDA972,131.45M848.90M
Diluted EPS4,110.273.58
Dividends Per Share735.290.64
Total Assets5,697.32B4,792.70M
Total liabilities1,623.74B1,365.92M
Total equity3,940.44B3,314.77M
Operating cash flow901,686.05M787.38M
Currency in KRWCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 949,079.96M 982,074.95M 1,128.45B 1,849.11B 1,911.60B
Gross Profit 685,318.99M 544,684.88M 623,118.64M 1,016.64B 1,064.37B
Operating income 507,771.41M 322,728.11M 381,535.86M 718,579.05M 752,471.48M
Income before tax 491,503.19M 302,159.30M 382,510.47M 654,561.59M 751,917.45M
Net income 382,467.03M 245,755.01M 301,030.34M 517,759.53M 575,093.26M
EBITDA 605,721.68M 447,554.58M 535,255.48M 892,388.45M 972,131.45M
Diluted EPS 2,686.06 1,718.77 2,157.42 3,702.99 4,110.27
Dividends Per Share 0 0 0 0 735.29
Total Assets 3,410.79B 3,590.82B 3,859.64B 5,020.12B 5,697.32B
Total liabilities 975,863.55M 992,561.59M 983,733.41M 1,589.54B 1,623.74B
Total equity 2,308.89B 2,486.50B 2,760.10B 3,307.67B 3,940.44B
Operating cash flow 482,870.20M 354,768.82M 468,031.66M 342,017.88M 901,686.05M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 839.51M 892.37M 967.65M 1,567.19M 1,669.28M
Gross Profit 606.20M 494.93M 534.32M 861.64M 929.45M
Operating income 449.15M 293.25M 327.16M 609.02M 657.08M
Income before tax 434.76M 274.56M 328.00M 554.76M 656.60M
Net income 338.31M 223.30M 258.13M 438.82M 502.19M
EBITDA 535.79M 406.67M 458.98M 756.33M 848.90M
Diluted EPS 2.37 1.56 1.85 3.13 3.58
Dividends Per Share 0 0 0 0 0.64
Total Assets 3,186.01M 3,218.15M 3,337.49M 4,621.30M 4,792.70M
Total liabilities 911.55M 889.55M 850.64M 1,463.26M 1,365.92M
Total equity 2,156.73M 2,228.44M 2,386.70M 3,044.90M 3,314.77M
Operating cash flow 427.12M 322.36M 401.33M 289.87M 787.38M

Valuation Measures

Dec 2021
PER47.94
ROA10.73%
ROE15.86%
Operating margin39.36%
Profit margin30.08%

Key executives

  • Chief Executive Officer & Director: Wu-Sung Ki
  • Finance Director: Ho-Seop Lee
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Sang-Joon Lee
  • Vice President: Jung-Won Yoon

Shareholders

  • SEO JUNG-JIN (22.1%)
  • National Pension Service of Korea (7.3%)
  • Temasek Holdings Pte Ltd. (Investment Management) (4.9%)
  • The Vanguard Group, Inc. (1.9%)
  • Celltrion, Inc. (1.7%)
  • BlackRock Fund Advisors (1.4%)
  • Norges Bank Investment Management (0.8%)
  • Samsung Asset Management Co., Ltd. (0.6%)
  • Mirae Asset Global Investments Co., Ltd. (0.6%)
  • BlackRock Advisors (UK) Ltd. (0.5%)

Contact Details

Related Companies

  • Celltrion Asia Pacific Pte Ltd.
  • Celltrion Group Hong Kong Ltd.
  • Celltrion Biopharma Ltd.
  • Celltrion USA, Inc.
  • Celltrion Global Safety Data Center, Inc.
  • Celltrion Europe Ltd.
  • Vcell Healthcare Ltd.
  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.

Competitors

  • Novartis AG
  • Biocon Limited
  • AbbVie, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Biogen Inc.
  • Teva Pharmaceutical Industries Limited
  • Gilead Sciences, Inc.
  • AstraZeneca PLC
  • Fresenius SE & Co. KGaA
  • Bio-Thera Solutions, Ltd. Class A
  • Sanofi
  • Regeneron Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc. Class A
  • Glenmark Pharmaceuticals Limited
  • GSK plc
  • Sam Chun Dang Pharm. Co., Ltd.
  • Viatris, Inc.
  • Alnylam Pharmaceuticals, Inc
  • Formycon AG
  • Luye Pharma Group Ltd.
  • Kirin Holdings Company, Limited
  • Sorrento Therapeutics, Inc.
  • Merck KGaA
  • SAMSUNG BIOLOGICS Co., Ltd.
  • FUJIFILM Holdings Corp
  • Cidara Therapeutics, Inc.
  • Generation Bio Co.
Last Updated on 4 Oct, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more